The purpose of this study was to assess the efficacy, safety and tolerability of Mirabegron and behavioral combination versus Mirabegron alone in the treatment of women with overactive bladder (OAB).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
600
mirabegron 50mg QD for 12 weeks.
Change From Baseline in Overactive Bladder Symptom Score (OABSS) Total Score
Time frame: From first dose of study drug up to month 9
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Time frame: From first dose of study drug up to month 9
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.